SPRY
ARS Pharmaceuticals, Inc
NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY
$8.26
+5.36% today
Updated 2026-04-30
Market cap
$788.42M
P/E ratio
—
P/S ratio
9.36x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$7 – $19
Volume
1.5M
ARS Pharmaceuticals, Inc (SPRY) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $17.84M | $5.51M | $1.32M | $30000.00 | $89.15M | $84.28M |
| Revenue growth (YoY) | — | — | — | -69.1% | -76.1% | -97.7% | +297063.3% | -5.5% |
| Cost of revenue | $1.42M | $1.55M | $14.07M | $213000.00 | $17.12M | $73000.00 | $20.56M | $20.42M |
| Gross profit | $-1.42M | $-1.55M | $3.77M | $5.29M | $-15.80M | $30000.00 | $68.59M | $63.85M |
| Gross margin | — | — | 21.1% | 96.1% | -1200.9% | 100.0% | 76.9% | 75.8% |
| R&D | $14.80M | $21.50M | $14.07M | $20.27M | $18.38M | $20.27M | $19.58M | $13.18M |
| SG&A | — | — | $4.23M | $4.69M | $18.46M | $47.28M | $71.67M | $230.12M |
| Operating income | $-18.32M | $-24.07M | $-469000.00 | $-19.45M | $-35.52M | $-67.52M | $-3.08M | $-179.45M |
| Operating margin | — | — | -2.6% | -353.3% | -2698.8% | -225066.7% | -3.5% | -212.9% |
| EBITDA | $-16.90M | $-22.52M | $-463000.00 | $-19.24M | $-35.20M | $-67.45M | $-3.00M | $-178.08M |
| EBITDA margin | — | — | -2.6% | -349.5% | -2674.5% | -224823.3% | -3.4% | -211.3% |
| EBIT | $-18.32M | $-24.07M | $-469000.00 | $-19.45M | $-35.52M | $-67.52M | $-3.08M | $-179.45M |
| Interest expense | — | — | $29000.00 | $106000.00 | $834000.00 | — | $0.00 | $2.60M |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.58M | $-23.97M | $-1.06M | $-20.24M | $-34.68M | $-54.37M | $8.00M | $-171.30M |
| Net income growth (YoY) | — | -36.3% | +95.6% | -1800.8% | -71.3% | -56.8% | +114.7% | -2241.8% |
| Profit margin | — | — | -6.0% | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |